Overview

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerabiltiy, and pharmacodynamics of different multiple dose regimens of RDX5791 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Ardelyx
Treatments:
Psyllium